The Role of Evolutionary Intermediates in the Host Adaptation of Canine Parvovirus


1Baker Institute for Animal Health, Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
2Center for Infectious Disease Dynamics, Department of Biology, The Pennsylvania State University, University Park, PA 16802, USA
3Division of Infectious Diseases, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
4Fogarty International Center, National Institutes of Health, Bethesda, MD 20892, USA
5Present address: Centro de Biotecnología y Genómica de Plantas (UPM-INIA) and E.T.S.I. Agrónomos, Campus de Montegancedo, Universidad Politécnica de Madrid, Pozuelo de Alarcón, Madrid, Spain
6Present address: Baylor College of Medicine, Department of Molecular Virology and Microbiology, Houston, TX 77030, USA
7Present address: Shannon Veterinary Services, Jefferson, GA 30549, USA
*Corresponding author:
Baker Institute for Animal Health, Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
Telephone: (607) 256-5649; Fax: (607) 256-5608; email: crp3@cornell.edu
Evolutionary intermediates of paroviruses

Running title: Evolutionary intermediates of paroviruses

Word count: Abstract = 193; Main text = 4,847; Figures = 4; Tables = 2
The adaptation of viruses to new hosts is a poorly understood process likely involving a variety of viral structures and functions that allow efficient replication and spread. Canine parvovirus (CPV) emerged in the late 1970s as a host-range variant of a virus related to feline panleukopenia virus (FPV). Within a few years of its emergence in dogs, there was a worldwide replacement of the initial virus strain (CPV type-2) by a variant (CPV type-2a) characterized by four amino acid differences in the capsid protein. However, the evolutionary processes that underlie the acquisition of these four mutations, as well as their effects on viral fitness, both singly and in combination, are still uncertain. Using a comprehensive experimental analysis of multiple intermediate mutational combinations, we show that these four capsid mutations act in concert to alter antigenicity, cell receptor binding, and relative in vitro growth in feline cells. Hence, host adaptation involved complex interactions among both surface-exposed and buried capsid mutations that together altered cell infection and immune escape properties of the viruses. Notably, most intermediate viral genotypes containing different combinations of the four key amino acids possessed markedly lower fitness than the wildtype viruses.
Evolutionary intermediates of parvoviruses

Ongoing viral evolution may generate important phenotypic variants, including strains that differ in host range, transmission mechanisms and efficiency, tissue tropism, antigenicity, and/or virulence. Although these novel biological functions often require multiple and concerted genomic changes, how such combinations of mutations can arise and be favored by natural selection is unclear. The complexity of the evolutionary pathways leading to the appearance of phenotypic variants is compounded when they alter the host range of viruses, as mutations may have different fitness consequences in different host species (24, 27, 32). Mutations may also be subject to complex selection pressures in the same host when, for example, receptor binding and antibody recognition sites overlap on the viral capsid, so that selection pressures differ between immunologically naïve and immune individuals (31). Understanding the processes by which viruses acquire new phenotypes in the face of such complex selective environments is critical for improving the prediction, prevention and control strategies for emerging viral diseases.

Feline panleukopenia virus (FPV) and closely related viruses that infect many hosts within the order Carnivora have undergone processes of cross-species transmission and adaptation during the last three decades, providing a powerful opportunity to examine the evolution and adaptation of a novel pandemic virus in the context of new host environments. CPV-2 is a host-range variant of a virus closely related to FPV that gained the ability to infect dogs through the acquisition of capsid mutations that altered the interaction of virus capsids with the transferrin receptor type 1 (TfR) on the surface of canine cells (14, 29). CPV type-2 (CPV-2) was the original virus strain in dogs that spread worldwide during 1978 and that was completely replaced during 1979 and 1980 by a new variant (CPV-2a). The CPV-2a strain is genetically and antigenically distinct from CPV-2 (17, 22), and is presumably better adapted to its canine host since it replaced CPV-2 in nature. It is now clear that the emergence of CPV involved a number
Evolutionary intermediates of parvoviruses

of host-switching events between cats, dogs, raccoons, and possibly other carnivores, with multiple transfers occurring among the different hosts (2). While the emergence of CPV-2a was previously attributed to host adaptation in dogs, recent studies have shown that this adaptive process likely involved transfer of CPV-2a to and from raccoons (2). Raccoon infection also involved a host-range change in the virus, as the raccoon viruses lost the canine host range and appeared to carry host-specific mutations that were likely adaptive for raccoons (2). The emergence of CPV-2a also involved a host-range expansion, as the original CPV-2 did not replicate in cats, while CPV-2a isolates replicated efficiently and caused disease in cats (28). This represented a novel host-adaptation event, as CPV-2a did not show significant reversion back to the original FPV sequences (28). CPV-2a isolates also showed altered binding to the feline TfR compared with either FPV or CPV-2 (9), and were antigenically variant at both of the major antigenic epitopes on the capsid (22).

All CPV-2a-derived viruses isolated from dogs share four unique amino acid replacements compared with CPV-2, at residues 87, 101, 300, and 305 in the capsid protein, VP2 (Table 1, Fig. 1). The CPV-2a-specific residues at 87 (Leu) and 101 (Thr) were likely acquired during evolution of the virus in raccoons, while the changes at 300 (Gly) and 305 (Tyr) were acquired when the virus transferred back to the canine host (2). Importantly, residues 87, 300 and 305 all lie within the proposed binding footprint of the TfR, while residue 101 lies close to residue 87 just below the capsid surface (Fig. 3) (7). In the three decades since its emergence, the CPV-2a-derived variants have acquired many additional point mutations, and some codons have changed multiple times. For example, VP2 residue 426 is Asn in the CPV-2a virus, but Asp in the CPV-2b-designated variants (16) and Glu in CPV-2c-designated variants (4), while...
VP2 residue 300 has been found as Ala, Gly, Val, Asp, and Pro in different viruses, and some of those variant residues alter host range and antigenicity of the viruses (2, 11, 19).

The structures of CPV and FPV capsids have been determined by X-ray crystallography, revealing that the capsid is a T=1 icosahedron, assembled from 60 subunits of a combination of VP1 (about 5 to 7 copies) and VP2 (53 to 55 copies) (1, 30, 35). VP1 and VP2 share most of their sequence, as VP2 is completely contained within the sequence of VP1. The common VP structure includes a central core that is made up of an eight-stranded $\beta$-barrel, where loops between the $\beta$-strands interact to assemble the capsid and also form most of the capsid surface (30, 35). The TfR binding site on the capsid is on a raised region of the structure (the threefold spike) and overlaps extensively with one of the two antigenic sites on the capsid surface, termed sites A and B (6, 26). Both antibody-selected and host-range-controlling sites on the capsid fall within the antigenic sites, with VP2 residue 300 in the middle of site B, residue 426 within site A, and residues 87 and 305 within an overlapping region of the antibody binding footprints for sites A and B (6).

To study the impact of the four mutations at VP2 residues 87, 101, 300, and 305 on CPV binding and infection properties, the order and/or combinations in which these mutations may have evolved, and the nature of the fitness pathways followed during the process of viral adaptation, we examined several biological properties of viruses that represent all intermediate combinations of the four CPV-2a-clade-defining VP2 residues in the backgrounds of viral genomes from the CPV-2 and CPV-2a clades. Importantly, none of these potential intermediate viruses have ever been isolated from clinical canine cases, although some of the mutational combinations are present in viruses from raccoons, albeit in different, host-specific genetic backgrounds (2).
MATERIALS AND METHODS

**Cells and viruses.** Norden Laboratory feline kidney (NLFK) cells and A72 canine fibroblasts were grown in a 1:1 mixture of McCoy’s 5A and Liebovitz L15 media with 5% fetal calf serum (FCS) (growth medium). Parvoviruses were derived from infectious plasmid clones of CPV-2 (CPV-d) and CPV-2b (CPV-39) strains, as previously described (16). Intermediate viruses were created from the same infectious plasmid clones using either the GeneEditor *in vitro* Site-Directed Mutagenesis System (Promega, Madison, WI) or the Phusion Site-Directed Mutagenesis Kit (Finnzymes, Woburn, MA). In all cases, the mutated region of the VP2 gene was sequenced to confirm that only the desired mutations were present, and in some cases, the mutated region was recloned into the appropriate infectious plasmid background to ensure no additional mutations were present in the genome. Capsids were purified from infected cells by concentration with polyethylene glycol, followed by sucrose gradient centrifugation and dialysis against phosphate buffered saline (PBS) (1, 12).

**Virus infectivity assays.** For viability and infection assays, NLFK cells seeded at $2 \times 10^4$ cells/cm$^2$ in 25 or 75 cm$^2$ dishes were incubated overnight at 37°C. To prepare infectious virus, cells were incubated with 5 μg plasmid DNA and Lipofectamine (Invitrogen, Carlsbad, CA) for 4 hrs. Transfected cell cultures were grown for 7 days with one passage. To assess virus infectivity, cells were inoculated with first passage virus supernatant and then incubated for 7 days. Viral infection was assessed by examining cells for viral proteins, where coverslips were fixed two days post-transfection or post-infection and analyzed by immunofluorescence microscopy (IFA). Transfected or infected cultures were frozen, thawed, and centrifuged at
Evolutionary intermediates of parvoviruses

10,000 × g for 10 mins. Virus titers were tested in hemagglutination (HA) assays using feline erythrocytes in Bis-Tris buffered saline (pH 6.2 at 4°C) (20, 25).

Virus detection by fluorescence antibody staining. Fixed cells were stained for virus with Alexa488-labeled anti-nonstructural protein-1 (NS1) mAb (CE10) (37) and/or Alexa594-labeled anti-capsid mAb (mAb 8) (20). Anti-viral antibodies were diluted in PBS containing 1% bovine serum albumin, 0.1% Triton X100 and 0.05% sodium azide (permeabilization solution) and incubated with cells for 1 hr at room temperature. Stained coverslips were analyzed with a Nikon Eclipse TE300 epifluorescent microscope.

Antigenic analysis of viruses. Antigenic testing of viruses was performed using a hemagglutination inhibition (HI) assay with a panel of mouse and rat mAbs prepared against FPV, CPV-2 or CPV-2b capsids (18, 20, 22) (Table 2).

Virus binding and uptake by feline and canine cells. Feline or canine cells were seeded at 2 × 10^4 cells/cm^2 in 12-well tissue culture plates. Following overnight incubation at 37°C, cells were washed twice with DMEM with 0.1% BSA (binding medium) at 37°C.

Wildtype and intermediate virus binding and uptake was examined by incubating cells with 15 μg/ml of purified virus for 1 hr at 37°C. Cells were washed twice with binding medium and dissociated with a brief exposure to trypsin and transferred to a 96-well, V-bottom plate, and then washed once with PBS containing 1% ovalbumin, 1 mM EDTA and 0.01% NaN3 (wash solution) before being fixed for 20 mins in IC fixation buffer (eBioscience, San Diego, CA). Cells washed three times with permeabilization buffer (eBioscience) were stained with Alexa488-labeled anti-capsid mAb 8 (20) for 30 mins at room temperature. After washing, cells were resuspended in wash solution and analyzed using a GuavaCyte flow cytometer (Millipore,
Evolutionary intermediates of parvoviruses

Billerica, MA). Flow cytometry data was analyzed using FlowJo v9 software (Treestar, Ashland, OR).

**Competition assays to assess relative viral fitness in cell culture.** Virus mixtures were prepared for each intermediate virus and its respective wildtype virus at 10:1, 1:1, and 1:10 volume-to-volume ratios. NLFK cells seeded at $2 \times 10^4$ cells/cm$^2$ in 96-well tissue culture plates were washed after 24 hrs with DMEM with 0.1% BSA (infection medium) at 37°C. Each virus mixture was incubated in a plate with cells for 1 hr at 37°C, then cells were washed twice with infection medium and maintained at 37°C for 2 or 7.5 days in growth medium. Cultures were frozen at -80°C, thawed rapidly at 37°C, transferred to a 96-well V-bottom plate and centrifuged at 1000 $\times$ g for 5 mins to pellet cellular debris. The supernatants were used for PCR and sequencing of the viral DNA. Two types of replicate competition assays were performed using either the same input stock viruses (competition replicates) or using different input stock mixtures (input replicates).

**PCR, sequencing and analysis.** Phusion hot start DNA polymerase (Finnzymes), CPV primers (forward 5'-GAAAACGGATGGGTGGAAATCACAGC-3' and reverse 5'-TATTTTGAATCCAATCTCCTTCTGG-3') and 30 cycles of 0:10 mins at 98°C, 0:30 mins at 54°C, 2:15 mins at 72°C amplified the mid-portion of the VP2 gene covering codons 87, 101, 300 and 305. DNA products were purified using QIAquick 96 PCR purification kits (Qiagen, Valencia, CA), and sequenced by Cornell University’s Core Laboratories Center using the same primers. Peak heights were measured from sequence traces using 4Peaks software (Mekentosj, Amsterdam, The Netherlands), and peak height ratios (PHR) were calculated for nucleotides that differed in sequence between each pair of input viruses. PHRs were defined as intermediate virus relative to wildtype virus or, in the case of the wildtype competition, as CPV-2b relative to
Evolutionary intermediates of parvoviruses

CPV-2. Changes in PHR over time were calculated, and fold increases or decreases after 2 or 7.5 days of cell culture incubation were determined. We defined an increase in PHR over time as indicating that the intermediate virus grew better than wildtype, whereas a decrease in PHR indicated that the wildtype virus grew better. Where more than one nucleotide varied between the two input viruses, the fold changes in PHR were calculated for each site independently and also averaged for all variant sites.

Statistical analysis for competition assays. To test for a statistically significant change in PHR over time, mixed models were fitted to the data using PROC MIXED in SAS v9.2 (SAS Institute Inc., Cary, NC) for each pairwise competition at both 2 days (data not shown) and 7.5 days post infection. The predictors used in the mixed models were virus pair, competition replicate, input replicate, and ratio (when all three ratios were analyzed together). Each competition replicate was modeled by its corresponding input replicate and each ratio by virus pair. Least squared means were compared adjusting for multiplicity using the Tukey-Kramer method. Data were analyzed for each residue and input ratio independently (data not shown), as well as for all residues and input ratios together.

RESULTS

We prepared 30 viruses with all single, double, triple, and quadruple VP2 mutations from each wildtype virus background, and tested these along with the two wildtype viruses. The available wildtype infectious clone used to represent the newer CPV-2a-like clade of viruses had an Asp at VP2 residue 426, making it the CPV-2b antigenic type. After the transfection of NLFK cells, 26 of the 30 intermediate viruses replicated well enough for further testing (Table 1). Four viruses replicated poorly in NLFK cells, and three of these were in the CPV-2b
Evolutionary intermediates of parvoviruses

background and involved changes at residues 101 or 300, or the combined change of residues 101 and 305 (Fig. 1). A fourth virus that replicated to very low levels was the triple intermediate in the CPV-2 background that gave the same combination of residues (87Leu, 101Ile, 300Gly, and 305Tyr) as one of the CPV-2b mutants that grew poorly.

**Antigenic variation.** The antigenic structure of the capsid changed significantly between CPV-2 and CPV-2a/b, with both the loss and gain of epitopes recognized by groups of mouse and rat mAbs (18, 20, 22). Multiple residues were involved in altering each antigenic site: the binding of the CPV-2-specific antibodies (mAbs D and J) was largely controlled by residues 87Met and 101Ile, while binding of CPV-2b-specific antibodies (mAbs 1D1, 7D6 and 7E2) was largely due to the change of residue 300 from Ala to Gly (Fig. 1A). The mAbs E and I gave unique binding patterns, and the results were not directly reciprocal between intermediate viruses where the same residues were changed in the two virus backgrounds. The mAb E showed reduced binding to CPV-2 intermediate viruses when residues 101 and 300 were changed together in the different double, triple and quadruple mutants. However, in the CPV-2b background, more than one combination of changes resulted in a recovery of mAb E binding. The binding of mAb I to CPV-2 was never lost, whereas all triple mutants of CPV-2b gained mAb I binding. These results indicate that the additional differences between the CPV-2 and CPV-2b capsids (Table 1) influence antibody binding by mAbs E and I.

**Receptor binding.** The binding and uptake of viruses in feline NLFK and canine A72 cells were assessed using flow cytometry (Fig. 1B). Comparing the wildtype viruses showed that CPV-2 capsids bound at 5- to 20-fold higher levels to feline and canine cells than did CPV-2b, as previously reported (9). Residues 87Met and 101Ile together were responsible for much of the higher binding seen in CPV-2, and changing these sites in CPV-2 to the CPV-2b residues, alone
Evolutionary intermediates of parvoviruses

and in concert, resulted in up to a 4-fold reduction in feline cell binding and up to a 15-fold reduction in canine cell binding. However, changing these two residues in CPV-2b to the CPV-2 sequence resulted in only a modest 1.5- to 4-fold increase in cell binding, and CPV-2b cell binding only reached CPV-2 levels when all four VP2 residues were changed simultaneously (Fig. 1B).

Relative fitness in cultured feline cells. The effects of the different mutations on the relative fitness of each of the intermediate viruses was determined by growing each virus in co-culture with its own wildtype virus in highly permissive feline NLFK cells. We determined the proportion of each of the viruses in the input mixture and at days 2 and 7.5 post infection from the relative peak heights at each differing position in the sequence trace (Fig. 2). Analyzing sequence data in this manner has been successfully used to identify heterozygotes (10), to detect SNPs in pooled samples of DNA (3, 34, 36), and to distinguish viral variants (8). Fig. 1C shows the change in proportion of each mutant virus compared with its own wildtype after 7.5 days of incubation. This shows that most single and double mutants were outcompeted by their respective wildtypes, while, surprisingly, the triple mutants infected or replicated more efficiently ($p < 0.005$ in most cases). This suggests that there are complex trade-offs in the effects of capsid mutations on viral functions, as revealed by this simple tissue culture assay.

In general, most CPV-2-derived intermediate viruses had lower replication fitness than wildtype CPV-2 in these feline cells (Fig. 1C). Changing VP2 residues 87 and 300 together in CPV-2 had the greatest effect, and resulted in a 40-fold decrease in the intermediate genome compared to the wildtype CPV-2 after 7.5 days incubation ($p < 0.0001$). Changing residue 305 alone resulted in a virus that replicated to similar levels as wildtype CPV-2. Interestingly, the three triple mutants tested in the CPV-2 background replicated significantly better than wildtype...
CPV-2, as evidenced by a 5-fold or greater increase after 7.5 days ($p \leq 0.0298$). However, changing all four residues in the CPV-2 background resulted in a virus less fit than wildtype CPV-2, matching similar results for the wildtype CPV-2b virus which grew to lower levels in cultured feline cells than did CPV-2 (data not shown).

The CPV-2b-derived intermediates showed a similar fitness pattern, with single and double mutants being of similar or lesser fitness than wildtype CPV-2b and triple mutants having greater fitness by up to 15-fold at 7.5 days post infection ($p < 0.0001$). Some of the CPV-2b-derived mutants with changes of residue 87 or 101 did not produce viable infectious viruses, and we confirmed that this was due to the specific mutations and not to problems with the genomic or plasmid background by re-cloning the segments containing the changes into fresh infectious plasmid clone backgrounds.

**Modeling CPV-2b structural changes.** Examining the structure of the capsid shows that the four residues all reside on the shoulder of the 3-fold spike, with residues 87 and 101 falling within the BC loop of one VP2 molecule, which interacts closely with the GH loop of a second VP2 that contains residues 300 and 305 (Fig. 3A) (35). Introducing the CPV-2b residues at positions 87, 101, 300, and 305 would be predicted to alter the flexibility of these surface loops and changes the hydrogen-bond interactions, as shown in Fig. 3B.

**The fitness landscape of intermediate viruses.** The data generated here can be used to infer a fitness landscape for CPV in the context of the *in vitro* test system used, with the example shown here (Fig. 4) representing the relative fitness of each CPV-2-derived virus in sequence space for this test environment. Importantly, this *in vitro* test system allows us to collect experimental fitness data that provides an initial understanding of the evolutionary pathways followed by CPV during the process of host adaptation. In the style of Weinreich et al. (33),
Figure 4B shows potential evolutionary trajectories, with pathways between the largest circles most parsimonious because they allow passage through the shallowest fitness troughs. Even in this simple \textit{in vitro} model utilizing a single cell type it is clear that the virus had to traverse a complex fitness landscape, with significant fitness valleys encountered during the evolution of CPV-2 to CPV-2a that would have clearly limited the number viable evolutionary pathways that could have been followed. In addition, the fitness landscape suggests that certain orders of mutational acquisition were more likely than others, with changes at residues 87 and 101 being favored before changes at residue 300 (Fig. 4B). Importantly, this pattern matches results from a phylogenetic analysis of canine and raccoon CPV isolates, in which the mutations at residues 87 and 101 preceded those at residues 300 and 305 (2).

**DISCUSSION**

The emergence of the CPV strains currently circulating in dogs involved two steps that each required the acquisition of multiple capsid mutations: the change from an FPV-like virus to CPV-2, and the change from CPV-2 to CPV-2a. Here, we examined the structural and functional relationships of the four conserved capsid mutations that distinguish the original and newer CPV strains by preparing all of the putative evolutionary intermediates between those viruses. The data obtained clearly show that these changes worked in concert to determine different aspects of viral phenotype. While intermediates between these two virus clades have not been isolated from dogs, some intermediate mutations have been identified in raccoons (2), albeit in unique, host-specific genetic backgrounds, suggesting that the evolutionary trajectory of these viruses was facilitated by passage through an alternative host.
While most of the intermediates showed reduced fitness in culture compared to the wildtype viruses, three of the 15 CPV-2b-derived intermediate viruses and one CPV-2-derived virus grew very poorly and could not be recovered in an infectious form for analysis. Viruses bearing 87Leu, 101Ile, 300Gly, and 305Tyr failed to grow in either the CPV-2 background (a triple mutant at residues 87, 300, and 305) or the CPV-2b background (a single revertant at site 101), which indicates that this constellation of residues is not well tolerated and less likely to be a true intermediate combination occurring during the early evolution of CPV.

Residue 300 and the adjacent residue 299 in VP2 have previously been shown to influence TfR and antibody binding (11, 15, 19, 26), and we now show that surface-exposed residues 87 and 305, as well as the closely positioned and buried residue 101, also play important roles in defining both of those binding activities. We do not yet have structures for the CPV-2a or CPV-2b capsids, but modeling the changes in the known CPV-2 or FPV capsid structures provides some predictions about the likely effects of changing different residues on the structure (Fig. 3B).

Mutations that change VP2 residues 87, 101 and 305 are all predicted to introduce changes in the geometry of the capsid structure due to both the substitutions of the amino acid side chains and the loss or gain of hydrogen bonds. Specifically, the change of residue 101 from Ile to Thr introduces a shorter side chain and a gain in polarity, so that the participation of 101Ile in a hydrogen bond with Met87 is likely lost (Fig. 3B). Two other hydrogen bonds arise from main chain interactions of the 101Ile, and introducing the shorter side chain may also cause a disruption of loop geometry that leads to loss of these main chain interactions. Similarly, the change of residue 87 from Met to Leu introduces a smaller side chain and causes the loss of the sulfur atom. The Met participates in two hydrogen bonds that would likely be disrupted resulting
Evolutionary intermediates of paroviruses

Finally the Asp to Tyr change of residue 305 causes the loss of a negative charge and introduces a bulkier side chain. The Asp is involved in hydrogen bonding that stabilizes the GH loop, so that the Tyr substitution likely causes loss of these stabilizing bonds, making the loop more flexible.

Antigenic variation. Each of the three surface-exposed residues influenced the antigenic structure of the viruses both alone and in concert with other changes, as expected since the residues fall within antigenic sites A and B on the capsid. Interestingly, changing the buried residue 101 also altered the antigenic structure, indicating that modifications at this site alter the BC loop structure and change the capsid surface. Antigenic selection likely played a role in the replacement of CPV-2 by CPV-2a (21), as the global population of dogs developed significant levels of antibody against CPV-2 within 2 years that may have selected for the variant antigenic forms of the CPV-2a and later CPV-2b capsids (18, 20, 22).

Control of receptor binding. CPV-2 binds feline and canine cells to a higher level than does CPV-2b (9), and here we show that both residue 87 and 101 influenced that binding, with only a minimal contribution from residue 305. In previous studies, changes of VP2 residues 299 and 300 to Glu or Asp, respectively, have proven to be particularly effective in altering host range. The change of residue 300 from Ala to Asp has been previously selected by growth of CPV-2 in feline cells in culture and that reduced infection for canine cells (11, 19), while natural raccoon isolates with 300Asp and other changes also lost the ability to infect canine cells (2). A CPV-2 mutant with only the VP2 residue 299 Gly to Glu substitution completely lost the ability to bind the canine TfR and infect canine cells (15, 26). It appears these host range changes are associated with changes in the surface structure and flexibility of capsid surface loops. Residue 300Asp forms a salt bridge with 81Arg in an adjacent VP2 subunit that would stabilize the
Evolutionary intermediates of parvoviruses

structure (11), while the 300Gly in CPV-2a would introduce more flexibility into that surface loop. The latter change likely aids virus binding to the canine TfR, which has an additional glycosylation site in the virus-binding region compared with the feline TfR (13).

Relative fitness. To examine the relative effects of the different combinations of mutations on virus infection and replication, we developed an assay for directly comparing cell infection and replication of each intermediate virus and its wildtype in feline cell culture. Although this system clearly does not recapitulate the natural history that occurred during the selection of CPV-2a over CPV-2 in dogs around the world, it does allow us to examine one aspect of viral replication in a single cell type that wildtype carnivore parvoviruses can infect with similar efficiency. Notably, single and double mutations reduced the replication of the viruses, while many triple combinations of mutations showed increased fitness over their respective wildtype genotypes. Although we do not yet have a clear explanation for this unusual effect, it does illustrate the complexity of the evolutionary pathways that would have been followed by the virus, particularly as the fitness landscape is characterized by major valleys that would have thwarted host adaptation (Fig. 4).

Similarly, although we have not found any of the CPV-2/CPV-2a intermediate mutational combinations in clinical isolates from dogs, viruses with various combinations of residues 87, 101, 300 and 305 are commonly found in raccoons (2). Phylogenetic analysis of these isolates showed that raccoon viruses that fall between the CPV-2 and CPV-2a clades have CPV-2a mutations at residues 87 (Leu) and 101 (Thr), but unique, host-specific changes at residues 300 (Asp) and occasionally 305 (His instead of the older CPV-2 Asp) (2). This suggests that the acquisition of at least some of these mutations may have arisen in viruses that were infecting...
raccoons, but the unique mutations at residues 300 and 305 indicate that raccoons provide a
different selective environment than dogs.

Although the four residues tested represent key differences between the CPV-2 and CPV-2a clades, several other nucleotide differences in the genomes of the two tested wildtype clones (CPV-2 and CPV-2b) may be influencing both their phenotypes and fitnesses (Table 1). For example, the CPV-2b-derived intermediate virus with all four residues changed to CPV-2 sequences was still outcompeted by wildtype CPV-2b, indicating that the viral background possesses other mutations that affect growth in feline cell culture compared with wildtype CPV-2. It is unclear which of these other mutations might be playing a role and how they influence in vitro fitness. The wildtype CPV-2 and CPV-2b plasmid clones used in these studies were prepared from viruses that had been passed only a small number of times in cell culture (16). They differ at seven nucleotide positions in noncoding sequences, three nucleotide positions in the nonstructural ORFs (including nonsynonymous changes at NS1 codon 544 and NS2 codon 152) and two nonsynonymous changes of VP2 codons 375 and 426 (Table 1). While these changes do not define the differences between the CPV-2 and CPV-2a clades in dogs (2, 23), these single nucleotide polymorphisms may also be influencing the properties of the viruses, at least in cell culture.

Precisely documenting the adaptation of a virus to a new host is critical to understanding viral emergence. Our results indicate that while the key mutations required for host adaptation may arise freely, there are only a limited number of evolutionary pathways that the virus can follow that lead to successful host adaptation, and this complexity will reduce the frequency of such host transfer events. In addition, it is clear that not only are multiple mutations required, but that many of these mutations act in concert and may need to be selected simultaneously to
Evolutionary intermediates of parvoviruses

overcome host fitness barriers. Furthermore, as seen here with cellular receptors and antibodies, combinations of changes can affect multiple interactions with the host concurrently, resulting in complex selection pressures at these sites. In sum, this study provides a clearer picture of the complexities involved in an important adaptive event that involved multiple host transfers.

ACKNOWLEDGEMENTS

We thank Dr. Shamil Sadigov from the Cornell Statistical Consulting Unit for his help with the statistical analysis of the competition data. We also thank Dr. Kai-Biu Shiu for his assistance with intermediate virus cloning, and Ms. Virginia Scarpino and Ms. Wendy Weichert for their expert technical support. This work was supported by National Institutes of Health (NIH) grants AI28385 and AI092571 to C.R.P. and GM080533-05 to E.C.H. K.M.S. was supported by NIH training grant RR007059 to Dr. Douglas D. McGregor, and I.P. was supported by Marie Curie Fellowship PIOF-GA-2009-236470.
Evolutionary intermediates of parvoviruses

REFERENCES


Evolutionary intermediates of paroviruses


Evolutionary intermediates of paroviruses


Table 1. Mutational differences between CPV-2 and CPV-2b, with grey indicating the residues examined in detail in this study. NS1 = non-structural protein 1; NS2 = alternatively spliced non-structural protein 2; VP2 = major capsid protein.

<table>
<thead>
<tr>
<th>Nucleotide Number</th>
<th>Genomic Region</th>
<th>CPV-2 Sequence</th>
<th>CPV-2b Sequence</th>
<th>CPV-2 Residue</th>
<th>CPV-2b Residue</th>
</tr>
</thead>
<tbody>
<tr>
<td>59</td>
<td>5' non-coding</td>
<td>G</td>
<td>A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>97</td>
<td>5' non-coding</td>
<td>C</td>
<td>T</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1649</td>
<td>NS1 residue 459</td>
<td>ATT</td>
<td>ATC</td>
<td>Synonymous</td>
<td></td>
</tr>
<tr>
<td>1903</td>
<td>NS1 residue 544</td>
<td>TAT</td>
<td>TTT</td>
<td>Tyr</td>
<td>Phe</td>
</tr>
<tr>
<td>2198</td>
<td>NS1 residue 642</td>
<td>ACA</td>
<td>ACG</td>
<td>Synonymous</td>
<td></td>
</tr>
<tr>
<td>2198</td>
<td>NS2 residue 152</td>
<td>ATG</td>
<td>GTG</td>
<td>Met</td>
<td>Val</td>
</tr>
<tr>
<td>3045</td>
<td>VP2 residue 87</td>
<td>ATG</td>
<td>TTG</td>
<td>Met</td>
<td>Leu</td>
</tr>
<tr>
<td>3088</td>
<td>VP2 residue 101</td>
<td>ATT</td>
<td>ACT</td>
<td>Ile</td>
<td>Thr</td>
</tr>
<tr>
<td>3685</td>
<td>VP2 residue 300</td>
<td>GCT</td>
<td>GGT</td>
<td>Ala</td>
<td>Gly</td>
</tr>
<tr>
<td>3699</td>
<td>VP2 residue 305</td>
<td>GAT</td>
<td>TAT</td>
<td>Asp</td>
<td>Tyr</td>
</tr>
<tr>
<td>3909</td>
<td>VP2 residue 375</td>
<td>AAT</td>
<td>GAT</td>
<td>Asn</td>
<td>Asp</td>
</tr>
<tr>
<td>4062</td>
<td>VP2 residue 426</td>
<td>AAT</td>
<td>GAT</td>
<td>Asn</td>
<td>Asp</td>
</tr>
<tr>
<td>4745</td>
<td>3' non-coding</td>
<td>T</td>
<td>C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4789</td>
<td>3' non-coding</td>
<td>T</td>
<td>C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4881</td>
<td>3' non-coding</td>
<td>C</td>
<td>T</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5026</td>
<td>3' non-coding</td>
<td>Deletion</td>
<td>G</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5029</td>
<td>3' non-coding</td>
<td>T</td>
<td>Deletion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 2. Wildtype virus specificity of monoclonal antibodies used to test intermediate virus antigenicity in the hemagglutination inhibition assay (18, 20, 22). The capsid binding site is indicated where it is known (6). ND = not defined previously

<table>
<thead>
<tr>
<th>mAb</th>
<th>Species</th>
<th>Immunizing Antigen</th>
<th>Binding Site on Capsid</th>
<th>CPV Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>J</td>
<td>rat</td>
<td>FPV-c</td>
<td>B</td>
<td>CPV-2</td>
</tr>
<tr>
<td>I</td>
<td>rat</td>
<td>FPV-c</td>
<td>A</td>
<td>CPV-2</td>
</tr>
<tr>
<td>D</td>
<td>rat</td>
<td>FPV-c</td>
<td>B</td>
<td>CPV-2</td>
</tr>
<tr>
<td>E</td>
<td>rat</td>
<td>FPV-c</td>
<td>B</td>
<td>CPV-2</td>
</tr>
<tr>
<td>1D1</td>
<td>mouse</td>
<td>CPV-39 (2b)</td>
<td>ND</td>
<td>CPV-2b</td>
</tr>
<tr>
<td>7D6</td>
<td>mouse</td>
<td>CPV-39 (2b)</td>
<td>ND</td>
<td>CPV-2b</td>
</tr>
<tr>
<td>7E2</td>
<td>mouse</td>
<td>CPV-39 (2b)</td>
<td>ND</td>
<td>CPV-2b</td>
</tr>
<tr>
<td>8</td>
<td>mouse</td>
<td>CPV-a (2)</td>
<td>B</td>
<td>All CPV</td>
</tr>
</tbody>
</table>

510 Table 2. Wildtype virus specificity of monoclonal antibodies used to test intermediate virus antigenicity in the hemagglutination inhibition assay (18, 20, 22). The capsid binding site is indicated where it is known (6). ND = not defined previously

511

Table 2. Wildtype virus specificity of monoclonal antibodies used to test intermediate virus antigenicity in the hemagglutination inhibition assay (18, 20, 22). The capsid binding site is indicated where it is known (6). ND = not defined previously

<table>
<thead>
<tr>
<th>mAb</th>
<th>Species</th>
<th>Immunizing Antigen</th>
<th>Binding Site on Capsid</th>
<th>CPV Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>J</td>
<td>rat</td>
<td>FPV-c</td>
<td>B</td>
<td>CPV-2</td>
</tr>
<tr>
<td>I</td>
<td>rat</td>
<td>FPV-c</td>
<td>A</td>
<td>CPV-2</td>
</tr>
<tr>
<td>D</td>
<td>rat</td>
<td>FPV-c</td>
<td>B</td>
<td>CPV-2</td>
</tr>
<tr>
<td>E</td>
<td>rat</td>
<td>FPV-c</td>
<td>B</td>
<td>CPV-2</td>
</tr>
<tr>
<td>1D1</td>
<td>mouse</td>
<td>CPV-39 (2b)</td>
<td>ND</td>
<td>CPV-2b</td>
</tr>
<tr>
<td>7D6</td>
<td>mouse</td>
<td>CPV-39 (2b)</td>
<td>ND</td>
<td>CPV-2b</td>
</tr>
<tr>
<td>7E2</td>
<td>mouse</td>
<td>CPV-39 (2b)</td>
<td>ND</td>
<td>CPV-2b</td>
</tr>
<tr>
<td>8</td>
<td>mouse</td>
<td>CPV-a (2)</td>
<td>B</td>
<td>All CPV</td>
</tr>
</tbody>
</table>
Figure 1. Ligand-binding properties and relative fitness of wildtype and intermediate viruses.

The left-most columns indicate the virus background and combination of four VP2 residue changes used for each intermediate virus, with white squares indicating CPV-2 residues (87Met, 101Ile, 300Ala, 305Asp) and black squares indicating CPV-2b residues (87Leu, 101Thr, 300Gly, 305Tyr). (A) Virus binding profiles for 8 mAbs as determined by HI assay. Strong (black), intermediate (grey) and weak (white) binding for each mAb was defined by its wildtype CPV-2 and CPV-2b binding titers, as wildtype virus specificity for these mAbs is well characterized (22). (B) Virus binding and uptake in feline and canine cells as measured by flow cytometry. The median fluorescent intensity (MFI) relative to CPV-2 binding from three independent experiments was averaged and the standard error of the mean is shown. (C) Relative fitness of intermediate viruses relative to wildtype CPV-2 (top half) or CPV-2b (bottom half) following 7.5 days of replication in feline cells. Average fold changes in intermediate relative to wildtype peak height ratios (PHRs) from three or more competition assays is shown. Asterisks indicate the change in PHR is significantly different from zero, or no change over time, with $p < 0.05$ (*) or $p < 0.005$ (**).
Figure 2. (A) Sequence trace data for the variable nucleotide in the VP2 codon 87 showing an increase in CPV-2 (green peak for adenine) and a decrease in CPV-2b (red peak for thymine) over time at each of the three input ratios of virus (10:1, 1:1, and 1:10). Traces are displayed using Geneious software (5). (B) Graphical representation of the change in peak height ratio (PHR) of CPV-2b relative to CPV-2 over time at each of the input ratios shown in (A). The decrease in PHR over time shows that the second virus (CPV-2) replicates to higher levels than the first (CPV-2b). pi = post-infection.
Figure 3. (A) Asymmetric unit of the CPV-2 capsid structure, showing the spatial relationships among the surface-exposed residues 87, 300 and 305 in red. Each VP2 peptide has a different color and three key surface loops are outlined in black. (B) A closer, three-dimensional representation of the CPV-2 structure, showing the four residues of interest in red and indicating with yellow arrows all potential hydrogen bonds that may be altered when these residues are changed to the CPV-2b sequence.
**Figure 4.** Graphical representations of the relative fitness of CPV-2 intermediate viruses.

(A) Adaptive landscape of the CPV-2 mutational intermediates tested here, showing the fitness effects of the four key VP2 residues that define the difference between the newer CPV-2a clade and the older CPV-2 clade. Each individual blue bar and corresponding black error bar represent peak height ratio (PHR) values following 7.5 days of infection in cultured feline cells (top half of Fig. 1C). Wildtype CPV-2 (left) is assigned a PHR value of zero; other PHRs are normalized to this value. On the right is the quadruple mutant in the CPV-2 background, representing a potential ancestral state of the CPV-2a clade. The X-axis represents the number of mutations from wildtype CPV-2, and the various combinations of single, double and triple mutants are distributed along the Y-axis in an arbitrary fashion. The numbers below each bar indicate which residues are changed from the CPV-2 sequence. An overlay colored to match PHRs provides a graphical representation of the landscape, showing fitness valleys and peaks.

(B) A bubble plot showing the evolutionary pathways available to CPV-2 during its adaptation to dogs. The X- and Y-axes are as above. Peak height ratios were shifted onto a positive scale and multiplied by the same arbitrary scaling factor to allow the smallest and largest values to be visualized on the same plot as circles of various diameters. The largest circle for each number of mutations is shown in red. Two intermediate viruses in the CPV-2 background had either significantly reduced fitness (changes at VP2 87/300) or were nonviable (changes at VP2 87/300/305 – marked by an X), effectively eliminating evolutionary pathways that use these combinations from plausible mutational trajectories. Lines indicate the remaining potential pathways, with the most parsimonious (i.e., shallowest) evolutionary pathway highlighted in red.